11,993 Shares in AtriCure, Inc. $ATRC Bought by Diversify Advisory Services LLC

Diversify Advisory Services LLC acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,993 shares of the medical device company’s stock, valued at approximately $448,000.

Other large investors have also bought and sold shares of the company. Smartleaf Asset Management LLC lifted its holdings in AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares during the period. Scotia Capital Inc. increased its stake in shares of AtriCure by 1.2% in the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after buying an additional 457 shares during the period. ProShare Advisors LLC increased its stake in shares of AtriCure by 6.6% in the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock valued at $349,000 after buying an additional 543 shares during the period. Captrust Financial Advisors raised its position in shares of AtriCure by 7.9% during the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock worth $314,000 after acquiring an additional 579 shares during the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of AtriCure by 5.3% during the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock worth $545,000 after acquiring an additional 683 shares during the last quarter. 99.11% of the stock is owned by institutional investors.

AtriCure Trading Down 0.3%

ATRC opened at $47.49 on Friday. The company has a fifty day moving average price of $35.42 and a two-hundred day moving average price of $31.72. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $48.46. The company has a market cap of $2.42 billion, a P/E ratio of 226.15 and a beta of 1.20. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter in the prior year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts predict that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other AtriCure news, insider Vinayak Doraiswamy sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the sale, the insider owned 86,511 shares of the company’s stock, valued at approximately $3,363,547.68. This trade represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the sale, the director owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. This represents a 13.51% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 44,246 shares of company stock valued at $1,691,895. 4.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ATRC shares. UBS Group reduced their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Finally, Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.